Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06495593 · ClinicalTrials.gov registry record · Phase 4
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
A Phase 4 study of Multiple Sclerosis (Relapsing Remitting), sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06495593: Recruiting Phase 4 study of Multiple Sclerosis (Relapsing Remitting), sponsored by University of California, San Francisco.
NCT06495593 is a Phase 4 study of Multiple Sclerosis (Relapsing Remitting) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 5 participants, below the 562-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06495593, a Phase 4 study of Multiple Sclerosis (Relapsing Remitting), is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
B cell-depleting therapies, such as ocrelizumab, are among the most effective medications currently available for the treatment of multiple sclerosis (MS). This suggests that B cells play a very important role in MS. While B cells are rapidly eliminated from the blood of patients treated with medications like ocrelizumab, little is known about how effectively B cells are eliminated from lymph nodes, which are important sites of B cell activation. This study is being conducted to determine to what extent B cells are targeted in lymph nodes following ocrelizumab treatment, which may have important consequences for long-term MS outcomes.
Conditions Studied
Interventions
- DRUG Ocrelizumab
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 4 |
What NCT06495593 shows while recruiting
NCT06495593 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 562-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT06495593 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06495593 about?
NCT06495593 is a clinical study titled "Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis". B cell-depleting therapies, such as ocrelizumab, are among the most effective medications currently available for the treatment of multiple sclerosis (MS). This suggests that B cells play a very important role in MS. While B cells are rapidly eliminated from the blood of patients treated with medica...
What is the current status of trial NCT06495593?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2025-02-04. Estimated completion is 2025-12-31.
What conditions does trial NCT06495593 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT06495593?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT06495593?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06495593 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06495593's enrollment target sits among peer trials
5 30th of 29 the lowest of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
ACTIVE NOT RECRUITING · Phase 4
-
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
COMPLETED · Phase 4
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI